What conditions qualify for medical cannabis in Mexico?

The 2021 reglamento does not enumerate conditions; physicians prescribe at their discretion. Common indications include refractory pediatric epilepsy (Dravet, Lennox-Gastaut), multiple sclerosis spasticity, chronic neuropathic pain, cancer-related pain/nausea/cachexia, Parkinson's, fibromyalgia, anxiety, sleep disorders, and PTSD.

Is Epidiolex available in Mexico?

Yes. Epidiolex (highly purified plant-derived CBD, GW Pharmaceuticals/Jazz) is available in Mexico through COFEPRIS pharmacy import for refractory epilepsy, particularly Dravet and Lennox-Gastaut syndromes. It is the same product approved by the U.S. FDA.

Is Sativex available in Mexico?

Yes. Nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is registered in Mexico through COFEPRIS for multiple sclerosis spasticity. It is the principal MS-spasticity product in the Mexican medical channel.

Can children get medical cannabis in Mexico?

Yes. The pediatric refractory-epilepsy pathway is the original Mexican medical-cannabis pathway, opened by the Elizalde family case in 2015. Epidiolex is the principal pediatric product. Pediatric prescribing happens primarily through specialty children's hospitals and pediatric neurologists.

Mexico Medical Cannabis — Eligible Conditions

Medical Disclaimer: This information is educational only and does not constitute medical advice. Cannabis affects everyone differently. Always consult a qualified healthcare provider before using cannabis, especially if you take other medications.

Last verified: April 2026

The Reglamento Leaves Indications to Physician Discretion

The 2021 reglamento itself does not enumerate eligible conditions; it leaves prescription to physician discretion within the COFEPRIS framework. In practice, the most common indications, drawn from physician reporting and patient-advocacy data:

Refractory Pediatric Epilepsy

Particularly Dravet syndrome and Lennox-Gastaut syndrome (LGS). This was the original pathway, opened by the Elizalde family case — the 2015 amparo won by Graciela "Grace" Elizalde's family to import CBD oil. Epidiolex (highly purified plant-derived CBD, GW Pharmaceuticals/Jazz Pharmaceuticals — the same product approved by the U.S. FDA) is available in Mexico through pharmacy import for refractory epilepsy.

Multiple Sclerosis (MS)

For MS-related spasticity, with imported nabiximols (Sativex) the principal product. Sativex is a 1:1 THC:CBD oromucosal spray approved in Europe and several Latin American countries, registered in Mexico through the COFEPRIS pharmacy channel.

Chronic Neuropathic Pain

Cannabis-based therapies are prescribed for chronic neuropathic pain — particularly post-surgical, post-stroke, post-spinal-cord-injury, and diabetic neuropathy. CBD-dominant oils are most commonly prescribed; THC-containing preparations are available but more difficult to obtain through Mexican pharmacy import.

Cancer-Associated Symptoms

Pain management, chemotherapy-induced nausea and vomiting (CINV), and cachexia are accepted indications. Mexican oncologists have, since the 2021 reglamento, increasingly incorporated cannabinoid therapies as adjunctive support.

Other Conditions at Physician Discretion

Based on aggregated physician reporting:

Parkinson's disease — for tremor, sleep, and end-of-day "off" periods.
Fibromyalgia — for chronic widespread pain and sleep disturbance.
Anxiety disorders — increasingly prescribed CBD-dominant; THC-containing preparations rarely.
Sleep disorders — including insomnia and disordered REM.
Post-traumatic stress disorder (PTSD) — at physician discretion.
Inflammatory bowel disease (IBD) — Crohn's, ulcerative colitis adjunctive support.
Migraine and chronic headache.

No Public Patient Registry

Unlike Canada, Germany, or U.S. medical programs, Mexico does not maintain a public patient registry tied to specific qualifying conditions. Physician judgment within the COFEPRIS pharmacy framework determines access.

The Pediatric Pathway — How It Started

The Elizalde family case is foundational. In 2015, the family of Graciela "Grace" Elizalde, a young girl with Lennox-Gastaut Syndrome, won a federal amparo to import CBD oil for her seizures. The case captured public attention, particularly through advocacy by mother Mayela Benavides and grandmother Grace Olivier de Bonilla. It directly catalyzed the 2017 Ley General de Salud reform under President Peña Nieto.

Pediatric refractory epilepsy remains the most-reported indication, in part because the case for medical necessity is most clinically clear (failure of multiple anti-epileptic drugs) and in part because the pediatric advocacy network (parent groups, the Cannativa organization) has been particularly effective.

Imported Product Origins

Product registration through COFEPRIS runs primarily through:

Canadian licensed producers — historically Aphria/Tilray, Canopy Growth (Tweed and Spectrum lines), Cronos.
U.S. CBD companies — including Charlotte's Web (via partners) and HempMeds Latam (from Medical Marijuana Inc.).
European pharma — GW/Jazz (Epidiolex, Sativex), German extractors.

Physician Knowledge Is Limited

Mexican medical schools have minimal cannabinoid education. Patients seeking cannabis-based therapy often educate their own physicians, particularly outside major metropolitan centers. Specialist clinics and physicians with cannabinoid familiarity cluster in:

Mexico City (CDMX) — particularly hospital networks affiliated with UNAM, IPN, and major private systems (ABC, Centro Médico ABC).
Guadalajara (Jalisco) — university-affiliated specialists.
Monterrey (Nuevo León) — TecSalud and other major systems.
Cancún — primarily expat-medical-tourism oriented.

Patient-advocacy organization Cannativa maintains physician-referral networks for new patients.

What Physicians Cannot Prescribe

Cannabis flower — excluded from the 2021 reglamento.
Edibles, beverages, topical creams — only registered pharmaceutical-preparation products.
Home-cultivation as therapy — that pathway is the amparo route, not the medical pathway. See amparo process.